CTOs on the Move

ChipCare

www.chipcare.ca

 
ChipCare is a Toronto based start-up company developing a point of care blood testing platform for the global health market. The Company`s diagnostic platform is extremely mobile, simple to use, inexpensive and produces laboratory quality results. From single drops of blood, health workers in remote locations can rapidly and accurately perform tests to diagnose or monitor a range of infectious and non-communicable diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.chipcare.ca
  • 101 College Street Suite 300
    Toronto, AB CAN M5G 1L7
  • Phone: 647.255.1378

Executives

Name Title Contact Details

Funding

ChipCare raised $18M on 11/17/2016

Similar Companies

Concuity

Concuity is a Vernon Hills, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CombiMatrix Corporation

CombiMatrix Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AMPAC Fine Chemicals

AMPAC Fine Chemicals (AFC) manufactures active pharmaceutical ingredients (APIs) and registered intermediates for customers in the pharmaceutical industry. Our integrated facilities are located in Rancho Cordova, California, approximately 20 miles east

A. M. Pappas

A. M. Pappas is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lykan Bioscience

The combined characteristics of a modern machine (with a touch of humanity) and mythical creature symbolizes Lykan Bioscience™ as a company. The team at Lykan Bioscience operates with a highly advanced way of thinking. We offer our clients speed, agility, and control while accelerating their cell and gene therapy products from clinical through to commercial manufacturing. As part of your team, our Manufacturing Services Organization™ (MSO) will transform what is traditionally offered in the CGT industry, as we guide you through your manufacturing journey. Our mission is to partner with our clients, to maximize patient accessibility and expedite time to market for cell-based therapies.